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Abstract: Type 2 diabetes mellitus (T2DM) is associated with a high risk of complications, 
essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary 
and cerebrovascular complications and the target level of glycated hemoglobin (HbA1c) in this 
population remains questionable. We here report the results of 4 recently published randomized 
controlled trials (ACCORD, ADVANCE, VADT, UKPDS post-trial), which did not demonstrate 
a significant reduction of cardiovascular events in the intensive group compared to the standard 
group. On the contrary, in ACCORD, the study with the most ambitious goal (HbA1c  6%), 
the overall and cardiovascular mortality was greater in the intensive group, although the risk of 
microangiopathic complications, especially nephropathy, was significantly decreased. VADT 
suggests that one possibility for the lack of observed effect of intensive therapy could be that 
the cardiovascular benefit is delayed. This contrasts strongly with the long-term postintervention 
outcomes of UKPDS, which show a persistent benefit of glycemic control during 10 years of 
post-trial follow-up (‘legacy effect’). Therefore, the best way to protect patients with T2DM 
against coronary and cerebrovascular disease is to target all cardiovascular risk factors as early 
as possible by an individualized approach.
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Introduction
The macro- and microvascular burden of type 2 diabetes mellitus (T2DM) is well 
established. Mortality from cardiovascular disease (CVD) is increased by a factor of 
2 to 3 in persons with diabetes mellitus compared with the general population.1 CVD 
develops earlier in the presence of diabetes mellitus and occurs as often in diabetic 
women as in diabetic men.1 A number of recent single risk factor intervention trials tar-
geting hyperglycemia, hypertension, dyslipidemia, procoagulation, microalbuminuria, 
and existing cardiovascular disorders have shown major beneficial effects on long-term 
outcome.2 However, the Steno-2 study with an intensive intervention for an average 
of 7.8 years, showed an event rate of the combined cardiovascular endpoint of 7% 
per year.3,4 Although the intensified multifactorial intervention cuts cardiovascular 
events as well as nephropathy, retinopathy, and autonomic neuropathy by about 
half, it is still more than three times as high as in the matched background popula-
tion, leaving much room for more improvements.3,4 To further reduce this increased 
risk, a multifactorial approach to the management of T2DM has now been advocated, 
and most of the updated national guidelines for the treatment of T2DM recommend 
a versatile approach driven by ambitious treatment targets. The American Diabetes 
Association (ADA), for example, recommends not only good glycemic control but Vascular Health and Risk Management 2009:5 860
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also identification and aggressive treatment of associated 
cardiovascular risk factors, with more stringent target levels 
for lipids and blood pressure (BP) than those recommended 
for the general population.5
Chronic hyperglycemia  
and cardiovascular disease:  
cause or link?
Though there is a link between hyperglycemia and 
cardiovascular risk, there is less evidence that glucose 
lowering is associated with reduction in CVD risk. Patients 
with T2DM whose glycated hemoglobin (HbA1c) levels were 
reduced from 8% to 7% in the United Kingdom Prospective 
Diabetes Study (UKPDS) did not exhibit a reduction in CVD, 
although a subgroup of patients treated with metformin had 
a lower risk of cardiovascular events.6 Among patients with 
type 1 diabetes mellitus (T1DM) studied in the Diabetes 
Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications trial (DCCT/EDIC), glucose 
lowering was associated with a long-term benefit with regard 
to cardiovascular complications that became apparent only 
years after recruitment.7,8
Four recent studies, the ACCORD (Action to Control 
Cardiovascular Risk in Diabetes) study,9 the ADVANCE 
(Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation) trial,10 
the VADT (Veterans Affairs Diabetes Trial)11 trial and the 
United Kingdom Prospective Diabetes Study Post-Trial 
(UKPDS post-trial) study,12 sought to determine the effect 
of lowering glucose to near-normal levels on cardiovascular 
risk. All studies share a number of common features, and 
were well designed and randomized. Each study was designed 
to evaluate the effects of intensive treatment for glycemic 
control in comparison to standard glucose-lowering targets 
on vascular outcomes in patients with T2DM who were 
considered to be at high risk.13 All studies evaluated an 
intensive blood-glucose-control strategy, rather than a specific 
therapeutic regimen, to achieve glycemic targets at levels 
well below those that are currently recommended. However, 
the trials differed substantially as displayed in Table 1. Thus, 
what did these studies show in more detail?
ACCORD
The ACCORD trial, a multicenter study of T2DM sponsored 
by the National Institutes of Health (NIH), was designed 
primarily to examine the effects of strict glycemic control 
on CVD in subjects with long-standing diabetes mellitus.5,9 
The study cohort of 10,250 adults (mean age 62 years) with a 
median diabetes duration of 10 years (including 35% already 
treated with insulin at baseline) and at high risk for CVD 
(diagnosed with CVD or 2 risk factors in addition to diabetes 
mellitus) was randomly assigned to an intensive treatment 
group with the aim of achieving HbA1c of  6% or a standard 
treatment group with an HbA1c goal of 7.0% to 7.9%.5,9 
The diabetes treatment strategies took advantage of an 
algorithmic approach using numerous diabetes medications 
in both study groups.5,9 In addition, in this factorial study, 
approximately one-half of the population was assigned to a 
BP study (intensive therapy aiming for systolic BP  120 
and conventional aiming for systolic BP  140 mmHg) and 
one-half to a lipid study in which all subjects were treated 
with a statin, but one-half randomly assigned to fenofibrate 
and one-half to placebo (see below).5,9
From a baseline median HbA1c of 8.1%, the intensive arm 
reached a median HbA1c of 6.4% compared to 7.5% in the 
control arm within 12 months of randomization.5,9 Compared 
to standard group, the use of insulin in combination with 
multiple oral agents, weight gain, and episodes of severe 
hypoglycemia was increased significantly more in the 
intensive treatment group.5,9
In 2008, the intensive blood sugar lowering arm of the 
study was halted based upon a recommendation of the 
external Data Safety Monitoring Board due to a higher 
number of total and cardiovascular deaths (257 vs 203) in 
subjects assigned to intensive therapy (HR 1.22; 95% CI 1.01 
to 1.46).5,9 However, the embedded BP and lipid studies are 
currently ongoing. Over an average of 3.5 years, there was 
an excess of three deaths per 1000 subjects per year in the 
intensive group. Notably, the rate of death in both treatment 
groups was lower than that reported in other studies of T2DM. 
The primary outcome (a composite of nonfatal myocardial 
infarction (MI), nonfatal stroke, or death from cardiovascular 
causes) occurred in 352 and 371 patients in the intensive 
and standard therapy groups, although this finding was not 
statistically significant (0.90 [0.78 to 1.04], P = 0.16).5,9
Extensive analyses have not identified a specific cause for 
the excess mortality.5,9 Subjects in the intensive group rapidly 
achieved target HbA1c values (median HbA1c decreased from 
8.1% to 6.7% in 4 months and was 6.4% after 3.5 years) and 
experienced a greater number of severe hypoglycemic events 
(annualized rate of 3.1 vs 1.0%) and more weight gain (mean 
3.5 vs 0.4 kg at 3 years) than the standard group.5,9 However, 
more frequent hypoglycemia did not apparently account for 
the difference in the death rate, nor did a specific medication 
or combination of medicines.5,9 The design of ACCORD 
limits the ability to determine whether the differences in Vascular Health and Risk Management 2009:5 861
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Table 1 Comparison of four trials of intensive glycemic control and CVD outcomes
ACCORD ADVANCE VADT UKPDS post-trial
Clinical trials  
NIH listing
NCT00000620  
see website  
http://clinicaltrials.gov
NCT00145925  
see website  
http://clinicaltrials.gov
NCT00032487  
see website  
http://clinicaltrials.gov
iSRCTN75451837  
see website  
http://controlled-trials.com
Design RCT,   AC, Phase iii RCT, PC, Phase iii RCT,   AC, Phase iii RCT,   AC, Phase iii
Participant characteristics
n 10,251 11,140 1,791 3,277
Mean age (years) 62 66 60 63
Duration of diabetes (years) 10 8 11.5 17
Sex (% male/female) 39/61 42/58 97/3 Si:60/40; M:46/54
History of CVD (%) 35 32 40 None
BMi (kg/m2) 32 28 31 Si:29; M:32
Mean baseline HbA1c (%) 8.1 7.5 9.4 Si:7.9; M:8,4
On insulin at baseline (%) 35 1.5 52 64
Protocol characteristics
HbA1c goals (%) (i vs S)a 6.0 vs 7.0–7.9 6.5 vs ‘based on 
local guidelines’
6.0 (action if 6.5) 
vs planned separation 
of 1.5
Aiming for fasting plasma 
glucose 6 mmol/L
Protocol for glycemic  
control (i vs S)a
Multiple drugs in 
both arms
Multiple drugs 
added to gliclizide vs 
multiple drugs with 
no gliclizide
Multiple drugs in 
both arms
intensive therapy (either 
sulfonylurea or insulin/Si  
or, min overweight 
patients, metformin/M) vs 
corresponding conventional 
therapy group/C (dietary 
restriction)
Management of risk factors embedded BP and 
lipid trials
embedded BP trial Protocol for 
intensive treatment 
in both arms
None
On study characteristics
Median duration of follow-up (years) 3.5 (terminated early) 5 5.6 8.8
Achieved median HbA1c (%) (i vs S)a 6.4 vs 7.5 6.4 vs 7.0 6.9 vs 8.5 Si:7.9 vs 7.9; M:8.1 vs 8.1
On insulin at study end (%) (i vs S)a 77 vs 55a 40 vs 24 89 vs 74 Data not shown
On TZD at study end (%) (i vs S)a 91 vs 58a 17 vs 11 53 vs 42 None
On statin at study end (%) (i vs S)a 88 vs 88a 46 vs 48 85 vs 83 Data not shown
On aspirin at study end (%) (i vs S)a 76 vs 76a 57 vs 55 88 vs 86 Data not shown
Smokers at study end (%) 10 8 8 Data not shown
Mean blood pressure at study  
end (mmHg)
intensive glycemic control arm 126/67 136/74 127/68 Data not shown
Standard glycemic control arm 127/68 138/74 125/69 Data not shown
Weight changes (kg)
intensive glycemic control arm +3.5 –0.1 +7.8 Si: +1.0
Standard glycemic control arm +0.4 –1.0 +3.4 M: –1.0
Severe hypoglycemia  
participants with 1 or more  
episodes during study (%)
intensive glycemic control arm 16.2 2.7 21.2 Data not shown
Standard glycemic control arm 5.1 1.5 9.9 Data not shown
(Continued)Vascular Health and Risk Management 2009:5 862
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Table 1 (Continued)
ACCORD ADVANCE VADT UKPDS post-trial
Outcomes
Definition of primary outcome Nonfatal Mi, nonfatal 
stroke, CVD death
Microvascular plus 
macrovascular (nonfatal 
Mi, nonfatal stroke, CVD 
death) outcomes
Nonfatal Mi, nonfatal 
stroke, CVD death, 
hospitalization for heart 
failure, revascularization
Any diabetes-related 
endpoint, diabetes-related 
death, death from 
any cause, Mi, stroke, 
peripheral vascular disease, 
microvascular disease
HR for primary outcome (95% Ci) 0.90 (0.78–1.04) 0.9 (0.82–0.98); 
macrovascular 0.94  
(0.84–1.06)
0.88 (0.74–1.05) Si:0.91 (0.83–0.99);  
M:0.79 (0.66–0.95)
HR for mortality findings (95% CI) 1.22 (1.01–1.46) 0.93 (0.83–1.06) 1.07 (0.81–1.42) Si:0.87 (0.79–0.96); 
M:0.73 (0.59–0.89)
*Medication rates for ACCORD are for any use during the study.
Abbreviations: AC, active control; BMi, body mass index; BP, blood pressure; C, conventional therapy; CVD, cardiovascular disease; i, intensive glycemic control; M, metformin group; 
Mi, myocardial infarction; PC, placebo control; RCT, randomized controlled trial; S, standard glycemic control; Si, sulfonylurea-insulin group;   TZD, thiazolidinedione.
glycemia between the treatment groups or the different profile 
of medications utilized to achieve the glycemic levels was 
responsible for the excess mortality.5,9
ADVANCE
The ADVANCE trial was designed to evaluate the effects of 
intensive glycemic and BP control on CVD in patient with 
long-standing T2DM at high risk for vascular disease.5,10 
The primary outcome endpoint was a combination of 
microvascular events (nephropathy and retinopathy) and 
major adverse cardiovascular events (MI, stroke, and 
cardiovascular death).5,10 The results of the BP-lowering arm 
are discussed further below.
In the intensive glucose lowering arm, 11,140 T2DM 
patients at high risk of CVD (mean age 66 years, mean 
duration of diabetes eight years) were randomly assigned 
to modified-release gliclazide (30 to 120 mg), plus other 
drugs as required, to achieve an HbA1c of  6.5% or to 
standard therapy (in which any medication but gliclizide 
could be used, with the glycemic target set according to 
“local guidelines”).5,10 Compared to ACCORD participants, 
patients with T2DM in ADVANCE were slightly older but of 
similar high CVD risk, the average duration of diabetes was 
about 2 years shorter, the baseline HbA1c (median 7.2%) was 
lower whereas almost no insulin was used at enrolment.5,10 
The primary endpoint was significantly reduced in the 
intensive glucose lowering arm (HR 0.90 [95% CI 0.82 to 
0.98], P = 0.01), although this was only due to a significant 
reduction of microvascular diabetic nephropathy classifed 
as development of macroalbuminuria (0.86 [0.77 to 0.97], 
P = 0.01), with no significant decline in the macrovascular 
outcome (0.94 [0.84 to 1.06], P = 0.32).5,10
After a median of 5 years of follow-up, the intensive 
and standard groups achieved mean HbA1c values of 6.5 and 
7.3%, respectively, with the HbA1c in the intensive group on 
average 0.67% lower.5,10 Severe hypoglycemia occurred in 
more patients in the intensively treated arm (2.7 vs 1.5%).5,10 
Mean body weight was 0.7 kg greater in the intensive 
compared with standard therapy group.5,10 Unlike the 
findings described above in the ACCORD trial, ADVANCE 
did not show an increased risk of death among patients 
receiving intensive therapy compared with standard therapy 
(HR for death from cardiovascular causes with intensive 
control 0.88, 95% CI 0.74 to 1.04; HR for death from any 
cause 0.93, 95% CI 0.83 to 1.06).5,10 As in ACCORD, there 
was no benefit of intensive therapy on the primary composite 
endpoint of cardiovascular death, nonfatal MI, or nonfatal 
stroke (HR 0.94, 95% CI 0.84 to 1.06) although the use 
of other cardioprotective drugs such as aspirin, statins or 
angiotensin-converting enzyme inhibitor (ACEI) was even 
lower in ADVANCE than in ACCORD or VADT.5,10
VADT
In the prospective VADT, investigators randomized 1791 
military veterans with T2DM (mean age 60 years, mean duration 
11.5 years, suboptimal response insulin or maximal-dose oral 
agents or standard glucose control) to a strategy of intensive 
glycemic control (goal HbA1c  6.0%) or standard glycemic 
control (planned HbA1c separation  1.5%).11 At the time of 
randomization, median HbA1c levels were 9.4% while nearly 
75% of patients had hypertension and 40% had a previous 
cardiovascular event.11
A variety of agents (metformin, glimepiride, rosiglitazone, 
insulin) were used to achieve glycemic goals.11 In both Vascular Health and Risk Management 2009:5 863
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study groups, obese patients were started on 2 drugs, 
metformin and rosiglitazone, whereas nonobese patients 
were started with glimepiride plus rosiglitazone.11 Patients 
in the intensive arm started on maximal doses.11 Insulin was 
added to most participants to achieve HbA1c levels less than 
6.0% in the intensive-treatment arm and less than 9.0% in 
the standard-therapy arm.11 Furthermore, aggressive BP, 
high levels of aspirin and statin usage, and a high degree of 
smoking cessation was acheived in both study groups.11
The primary outcome of VADT was a composite of CVD 
events (MI, stroke, cardiovascular death, revascularization, 
hospitalization for heart failure, and amputation for 
ischemia).5 After a median follow-up of 6.5 years, there 
was no significant difference in the first occurrence of 
any cardiovascular event (composite of stroke, death from 
cardiovascular causes, chronic heart failure, surgery for 
vascular disease, inoperable coronary disease, amputation 
for ischemic gangrene) between the intensive (achieved 
HbA1c 6.9%) and standard (HbA1c 8.4%) groups (HR in the 
intensive group 0.88, 95% CI 0.74 to 1.05).11 In addition, 
there was no difference between groups in time to death from 
cardiovascular causes (HR 1.32, 95% CI 0.81 to 2.14) or 
death from any cause (HR 1.07, 95% CI 0.81 to 1.42).11 Hypo-
glycemia occurred more frequently in the intensive group 
(8.5% vs 3.1%), including episodes with impaired or com-
plete loss of consciousness (12 vs 4 per 100 patient-years).11 
Post hoc subgroup analyses further indicated that participants 
with duration of diabetes 12 years appeared to have a 
CVD benefit of intensive glycemic control whereas par-
ticipants with loger duration of diabetes might experience 
even adverse effect of intensive glycemic control.11 Other 
exploratory analyses suggested severe hypoglycemia within 
the last 3 months as a predictor of CVD mortality, with an 
association of severe hypoglycemia with all-cause mortality 
apparent only for participants in the standard arm.5
UKPDS post-trial study
The original UKPDS was designed to investigate the 
role of glycemic control on the complications of T2DM 
in newly diagnosed patients.6 There was no difference in 
macrovascular disease in the intensive and conventional 
therapy groups (mean HbA1c values of 7% and 7.9%, 
respectively) in the primary analysis.6 A subset of 753 
overweight patients (mean BMI 31 kg/m2) was included in 
a separate treatment arm in which intensive blood glucose 
control with metformin was compared with conventional 
therapy.6 A secondary analysis compared the 342 patients 
allocated to metformin with 951 patients receiving intensive 
therapy with a sulfonylurea or insulin.6 Compared to 
conventional therapy, treatment with metformin resulted 
in significant risk reductions of 32% for any diabetes-
related endpoint (endpoints included both macrovascular 
and microvascular complications), 42% for diabetes-related 
death, and 36% for all-cause mortality.6 Metformin also had 
a greater effect upon any diabetes-related endpoint and all-
cause mortality than intensive therapy with a sulfonylurea 
or insulin (P = 0.003).6
Novel data from the UKPDS come from post-trial 
monitoring to follow up those patients either on conventional 
therapy (dietary restriction) or intensive therapy (either 
sulfonylurea or insulin or, in overweight patients, metformin) 
for a further 10 years, giving an overall median follow-up 
for the glucose control comparison of about 17 years.12 For 
the first 5 years of the post-trial monitoring, 3,227 patients 
were asked to attend annual UKPDS clinics but no attempts 
were made to maintain their previously assigned therapies.12 
In years 6 to 10 of this further follow-up, all patients were 
assessed only through questionnaires.12 The long-term 
clinical outcomes were assessed, according to the initial 
randomization, on an intention-to-treat basis.12
Notably, between-group differences in HbA1c levels 
were lost within one year of stopping the randomly assigned 
therapies.12 However, a surprising “legacy effect” emerged 
for both the sulfonylurea/insulin and the metformin groups, 
with significant reductions observed in MI and and in 
all-cause mortality in the intensive glycemic control group.12 
In the sulfonylurea/insulin group, relative reductions in risk 
persisted at 10 years for any diabetes-related outcomes (9%, 
P = 0.04), and microvascular disease (24%, P = 0.001) and 
risk reductions emerged over time for diabetes-related deaths 
(17%, P = 0.01), MI (15%, P = 0.01) and death from any 
cause (13%, P = 0.007) (12). In the metformin group, signifi-
cant reductions persisted for any diabetes-related endpoint 
(21%, P = 0.01), MI (33%, P = 0.005) and all-cause mortality 
(27%, P = 0.002).12
In summary, these results indicate that a sustained period 
of glycemic control over ten years in newly diagnosed 
patients with T2DM has a long-term benefit in reducing 
cardiovascular morbidity and mortality. The results are 
supported by similar findings from the postinterventional 
follow-up of subjects enrolled in the Steno-2 trial.4
Notably, in the above-mentioned glucose-lowering trials, 
other CVD risk factors were treated to a moderate or high 
degree, probably causing lower rates of CVD in the standard 
arm than originally predicted.5 Furthermore, most patients 
received multiple glucose-lowering drugs with distinct Vascular Health and Risk Management 2009:5 864
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pharmacological properties, either with or without insulin, to 
acheive blood glucose control in all studies. However, whereas 
in the ACCORD study glucose-lowering treatments to reach 
glycemic targets were not restricted to a single drug class, the 
ADVANCE study required sulfonylurea gliclazide (modified 
release) for all patients in the intensive-control group at least 
at initiation.5 While further comparing the ACCORD and 
ADVANCE studies, thiazolidinedione treatment was more 
frequently prescribed in the intensive-therapy group of the 
ACCORD trial which may interfere with the increase in 
mortality in ACCORD.5 As it will be further outlined below, 
both trials used a factorial design to test additional and dif-
ferent treatment interventions in their study participants. 
Participants of the ACCORD study were randomly assigned 
to undergo intensive therapy or standard therapy for BP 
lowering or to receive fenofibrate or placebo, whereas patients 
of the ADVANCE study were randomly assigned to receive 
a combination of perindopril and indapamide or to receive 
placebo.14 Surprisingly, neither study appears to have empha-
sized lifestyle or dietary modification – the solid rock of any 
treatment strategy in T2DM.
Most previous reviewers agree that the increase in 
mortality in ACCORD is probably due to the overall 
treatment strategies for intensifying glycemic control in 
the study population and not the achieved HbA1c per se.5 
In this context, it is important to emphasize that also dia-
betic patients in intensive arm of the ADVANCE study 
achieved a median HbA1c similar to that from patients of the 
ACCORD study while no increased mortality hazard was 
observed in the former study.5 Consequently, the increased 
mortality findings from the ACCORD study do not mean 
that patients with T2DM with low HbA1c levels due to 
lifestyle modifications or pharmacotherapy are at risk or 
even need to augment their HbA1c.5 Notably, the unfavor-
able cardiac effects of hypoglycemia, which are probably 
induced by a complex interplay of its overactivation of 
the sympathetic nervous system and cardiac dysrhythmia, 
have been mainly shown in T2DM with CVD or at high 
risk of sudden cardiac death and ventricular arrhythmias.15 
It is biologically plausible that once an event occurs, if the 
current glycemic control is too tight, this may predict an 
unfavorable outcome in view of the known detrimental 
cardiac effects of hypoglycemic episodes and events.15 
Furthermore, hypoglycemia unawareness probably due 
to diabetic autonomic neuropathy may aggravate this 
situation.15 Unfortunately, lethal hypoglycemic events are 
often erroneously considered as fatal coronary artery disease, 
mainly due to insufficient diagnosis criteria postmortem.5 
If hypoglycemia was indeed a contributing cause of death 
in the ACCORD trial, future studies of cardiovascular risk 
reduction should focus on achieving near-normal glycemic 
levels with the use of strategies and therapies associated 
with a lower risk of hypoglycemia.
Other plausible mechanisms for the increase in mortality 
in the ACCORD study population with advanced T2DM and 
multiple comorbidities include weight gain, distinct drug 
effects or interactions, or the use of multiple oral glucose-
lowering drugs along with multiple doses of insulin to 
rapidly acheive very low HbA1c targets.5 The recent findings 
from the UKPDS trial adds to this picture that glycemic 
control early in the course of T2DM may have CVD benefit 
which has been defined as “metabolic memory” or “legacy 
effect”.5,16 As is the case with microvascular complications, 
it may be that glycemic control plays a greater role before 
macrovascular disease is well developed and a minimal 
or no role when this detrimental complication is already 
advanced.5
In summary, although the evidence for CVD prevention 
by statin therapy, BP treatment, aspirin therapy in high-risk 
patients, and other interventions is robust,5 data on the effects 
of antihyperglycemic therapies are less evident. In T2DM, 
when other CVD risk factors are highly prevalent, the additive 
benefits of intensive glycemic control might be difficult to 
demonstrate except in even larger or longer trials.5 It is likely 
that a real benefit of glucose lowering on CVD in T2DM, even 
if it could be proven, is modest compared with and incremental 
to treatment of other established CVD risk factors.5
The beat is on: blood pressure 
control in T2DM patients
BP is an important determinant of the risk of macro- and 
microvascular vascular complications in patients with 
T2DM. Current European guidelines for the management 
of hypertension recommend lowering BP in patients with 
T2DM to reduce the risk of cardiovascular events.17 Guide-
lines also recognize the relevance of prediabetes, a situation 
characterized by the presence of the metabolic syndrome and 
consider the need for integral protection of the cardiovas-
cular and renal systems that includes a goal BP lower than 
130/80 mmHg, accompanied by strict metabolic and lipid con-
trol often accompanied by antiplatelet therapy.18 Furthermore, 
a reduction in the frequency of diabetic nephropathy by ACEI 
inhibitor treatment in normotensive lean microalbuminuric 
patients T2DM has been shown either.19 More recently, also 
beneficial effects with ARBs in hypertensive patients with 
T2DM and nephropathy have been demonstrated.20 In order Vascular Health and Risk Management 2009:5 865
Cardiovascular disease and glycemic control Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
to attain the adequate BP and cardiorenal protection beyond 
the BP decrease, suppression of the renin-angiotensin system 
(RAS) should therefore be attempted, usually in association 
with other antihypertensive drugs.18 Recently, the ONgoing 
Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET) compared the ACEI ramipril 
(10 mg/day), the angiotensin receptor blocker (ARB) 
telmisartan 80 mg/day, and the combination of the 2 drugs in 
25,620 patients with vascular disease or high-risk diabetes.21 
After a median follow up of 56 months, no significant dif-
ferences were observed between the 3 groups either in the 
primary composite outcome (death from cardiovascular 
causes, MI, stroke, or hospitalization for heart failure), 
or in each of its components, total mortality and other 
secondary outcomes.21 Telmisartan was equivalent to ramipril 
(noninferiority criterion), but was better tolerated (less cough 
and angioedema).21 The combination of the 2 drugs in this 
population (without congestive heart failure and proteinuric 
nephropathy), however, did not bring increased benefit (no 
superiority), but was associated with more adverse events 
(hypotension, syncope and renal dysfunction).21 In this popu-
lation, the choice of the molecule in monotherapy remains 
optional and the use of a dual blockade is not justified in 
order to have a better cardiovascular protection.21 Diuretics 
are often used as an adjunctive to reduce BP and form a very 
important basis for antihypertensive treatment, also often in 
combination with agents that inhibit the RAS.22,23 Several 
studies demonstrated that treatment with the diuretic inda-
pamide reduces the level of microalbuminuria in patients 
with T2DM.22,23 It is therefore understandable that many 
guidelines suggest that diuretics form part of the treatment 
of hypertension in patients with T2DM.17 However, adequate 
BP targets as indicated above cannot usually be reached using 
monotherapies especially in patients who present with a high 
cardiovascular risk such as T2DM.18
Thus, is the lower the better for BP control in T2DM 
patients or should we doubt such a conclusion in the light of 
increased mortality in the ACCORD trial? It is noteworthy to 
mention that clinical trials have reported a difference of 5 to 
6 mmHg between the diastolic BP of treatment and control 
groups; the risk reduction of 14% (95% CI 4% to 22%) for 
coronary events contrasts with the 20% to 25% reduction noted 
in epidemiologic reports.19 These discrepancies may be related 
to the existence of a J-shaped relationship between BP and 
risk, in which treated patients with low BP are at increased 
risk for coronary events.19 This effect is probably due to 
compromised coronary blood flow, especially in hypertensive 
patients with a history of MI, or to other factors independent 
from treatment with BP-reducing drugs such as deteriorating 
heath or pulse pressure.19 However, major epidemiological 
studies such as Framingham and the Multiple Risk Factor 
Intervention Trial (MRFIT) Diabetic Cohort showed that the 
J-shaped relationship between BP and mortality may not be so 
relevant.19,24,25 The latter study demonstrated that systolic BP 
and complications are clearly associated in diabetes patients 
without any threshold value while a 2- to 4-fold increase in 
cardiovascular mortality was observed.19,25 The UKPDS trial 
demonstrated that tight BP control (150/85 mmHg) resulted 
in a risk reduction compared with the less tight control arm 
(180/105 mmHg).26 Reductions in risk in the group assigned 
to tight control compared with that assigned to less tight control 
were 24% in diabetes related endpoints (95% CI 8% to 38%) 
(P = 0.0046), 32% in deaths related to diabetes (6% to 51%) 
(P = 0.019), 44% in strokes (11% to 65%) (P = 0.013), and 
37% in microvascular end points (11% to 56%) (P = 0.0092).26 
There was a nonsignificant reduction in all-cause mortality.26 
In the tight control group, 29% needed 3 or more antihyperten-
sive drugs.26 After 9 years of follow up, 29% of patients in the 
group assigned to tight control required 3 or more treatments 
to lower BP to achieve target BP.26 The HOT (Hypertension 
Optimal Treatment) study showed that the frequency of major 
CVD events (11.9/1000 patients/year) is significantly reduced 
in the group with a diastolic BP target  80 mmHg (achieved 
144/81 mmHg) was 11.9/1000 patients/year compared to 
the event rate (24.4/1000 patients/year) in the group with 
target  90 mmHg (achieved 148/85 mmHg).27 Thus, there 
is now increasing evidence that BP should be as low as 
possible in patients with T2DM.
A few months after the publication of the last European 
guidelines,17 the hypertension branch of the ADVANCE 
study was published.14 As it is agreed that multifactorial 
treatment regimens are required to reduce the cardio-
vascular burden in patients with T2DM, the ADVANCE 
study not only investigated the potential benefits of tighter 
glucose control (see above) but also the potential benefits 
of BP lowering, using the routine administration of an 
ACEI/diuretic combination (fixed low-dose combination 
of perindopril and indapamide vs placebo) irrespective of 
initial BP levels or the use of other BP lowering drugs.14 
The two primary outcomes, taken separately and jointly, 
are a composite macrovascular endpoint of nonfatal stroke, 
nonfatal MI and cardiovascular death, and a composite 
microvascular endpoint of new or worsening nephropathy 
or microvascular eye disease. After a 6-week active run-in 
period, 11,140 patients with T2DM were randomized to 
treatment with a fixed combination of perindopril and Vascular Health and Risk Management 2009:5 866
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indapamide or matching placebo (mean of 4.3 years of 
follow-up), in addition to current therapy.14 Compared with 
patients assigned placebo, those assigned active therapy had 
a mean reduction in systolic BP of 5.6 mmHg and diastolic 
BP of 2.2 mmHg.14 The relative risk of a major macrovascular 
or microvascular event was reduced by 9% (861 [15.5%] 
active vs 938 [16.8%] placebo; HR 0.91, 95% CI 0.83 to 
1.00, P = 0.04).14 The separate reductions in macrovascular 
and microvascular events were similar but were not inde-
pendently significant (macrovascular 0.92; 0.81 to 1.04, 
P = 0.16; microvascular 0.91; 0.80 to 1.04, P = 0.16).14 
The relative risk of death from CVD was reduced by 18% 
(211 [3.8%] active vs 257 [4.6%] placebo; 0.82, 0.68–0.98, 
P = 0.03) and death from any cause was reduced by 14% 
(408 [7.3%] active vs 471 [8.5%] placebo; 0.86, 0.75 to 
0.98, P = 0.03).14 There was no evidence that the effects of 
the study treatment differed by initial BP level or concomi-
tant use of other treatments at baseline.14 In conclusion, this 
study has shown that the addition of a fixed combination of 
perindopril and indapamide on top of the other medications 
in patients with diabetes with BP ranging from normal to 
elevated greatly helps diminish BP when required, while 
protecting the cardiovascular and renal systems from the 
deleterious effects of diabetes associated with high BP.14 This 
protection includes as the most relevant finding a significant 
decrease in all-cause death.14 Although the confidence limits 
were wide, the results suggest that over 5 years, 1 death 
due to any cause would be averted among every 79 patients 
assigned active therapy.14
Lately, the post-trial monitoring of patients in the UKPDS 
also examined whether risk reductions for microvascular and 
macrovascular disease, achieved with the use of improved BP 
control during the trial, would be sustained.28 Intriguingly, the 
benefits of previously improved BP control were not sustained 
when between-group differences in BP were lost.28 Thus, in 
contrast to the “metabolic memory” in the diabetic state, no 
“legacy effect” has been observed for hypertension.28
In conclusion, BP targets should aimed to be as low 
as possible in patients with T2DM. Furthermore, early 
improvement in BP control in patients with both T2DM 
and hypertension was associated with a reduced risk of 
complications, but it appears that good BP control must be 
continued if the benefits are to be maintained.
Implications for clinical care  
of T2DM patients
Intensive glycemic control is well established to avoid 
on microvascular and neuropathic complications in both 
T1DM and T2DM.5 The ADVANCE trial has added to that 
evidence base by demonstrating a significant reduction in the 
risk of new or worsening albuminuria when median HbA1c 
was lowered to 6.3% compared with standard glycemic 
control achieving an HbA1c of 7.0%.5 The lack of significant 
reduction in CVD events with intensive glycemic control in 
ACCORD, ADVANCE, and VADT, however, should not lead 
clinicians to abandon the general target of an HbA1c  7.0% 
and thereby disregard the benefit of adequate blood glucose 
control on devastating microvascular complications.5
The ADA’s Standards of Medical Care in Diabetes29 and the 
American Heart Association (AHA) and ADA’s scientific state-
ment on prevention further advocate controlling nonglycemic 
risk factors (through BP control, lipid lowering with statin 
therapy, aspirin therapy and lifestyle modifications) as the pri-
mary strategies for reducing the burden of CVD in people with 
T2DM.30 The lower-than-predicted CVD rates in ACCORD, 
ADVANCE and VADT, as well as the recent long-term follow-
up of the Steno-2 multiple risk factor intervention,4 provide 
strong evidence that optimal treatment for T2DM involves 
targeting of all vascular risk factors and not just hyperglycemia 
alone.5 The evidence for a cardiovascular benefit of intensive 
glycemic control remains strongest for those with T1DM.7,8 
However, subset analyses of ACCORD, ADVANCE, and 
VADT suggest the hypothesis that patients with shorter dura-
tion of T2DM and without established atherosclerosis may 
also achieve cardiovascular benefit from intensive glycemic 
control.5 In contrast, potential risks of intensive glycemic 
control may outweigh its benefits in other T2DM patients, 
eg, with long disease duration, severe hypoglycemia, pres-
ent atherosclerosis and advanced age/frailty.5 It is suggested 
that prevention of severe hypoglycemia in T2DM patients 
with advanced disease should be placed in the spotlight and 
aggressive normalization to near-normal HbA1c levels should 
be avoided in such patients.5 In conclusion, the evidence 
obtained from ACCORD, ADVANCE, and VADT does not 
suggest the need for major changes in glycemic control 
targets but, rather, additional clarification of the language 
that has consistently stressed individualization as stated in 
more detail lately in a position statement of the ADA and a 
scientific statement of the American College of Cardiology 
(ACC) Foundation and the AHA:5
•  Microvascular disease: Lowering HbA1c to below or 
around 7% has been shown to reduce microvascular and 
neuropathic complications of T1DM and T2DM. Therefore, 
the HbA1c goal for nonpregnant adults in general is 7%. 
ADA, A-level recommendation; ACC/AHA, class I 
recommendation (level of evidence A).Vascular Health and Risk Management 2009:5 867
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•  Macrovascular disease: In T1DM and T2DM, randomized 
controlled trials of intensive vs standard glycemic 
control have not shown a significant reduction in CVD 
outcomes during the randomized portion of the trials. 
However, long-term follow-up of the DCCT and UKPDS 
cohorts suggests that treatment to HbA1c targets below 
or around 7% in the years soon after the diagnosis of 
diabetes is associated with long-term reduction in risk 
of macrovascular disease. Until more evidence becomes 
available, the general goal of 7% appears reasonable. 
ADA, B-level recommendation; ACC/AHA, class IIb 
recommendation (level of evidence A).
For some patients, individualized glycemic targets other 
than the above general goal may be appropriate as stated by 
Skyler et al:5
•  Subgroup analyses of clinical trials such as the DCCT 
and UKPDS and the microvascular evidence from the 
ADVANCE trial suggest a small but incremental benefit 
in microvascular outcomes with HbA1c values closer 
to normal. Therefore, for selected individual patients, 
providers might reasonably suggest even lower HbA1c 
goals than the general goal of 7% if this can be achieved 
without significant hypoglycemia or other adverse effects 
of treatment. Such patients might include those with short 
duration of diabetes, long life expectancy, and no significant 
CVD. ADA, B-level recommendation; ACC/AHA, class IIa 
recommendation (level of evidence C).
•  Conversely, less stringent HbA1c goals than the general goal 
of 7% may be appropriate for patients with a history of 
severe hypoglycemia, limited life expectancy, advanced 
microvascular or macrovascular complications, or exten-
sive comorbid conditions or those with long-standing 
diabetes in whom the general goal is difficult to attain despite 
diabetes self-management education, appropriate glucose 
monitoring, and effective doses of multiple glucose-lowering 
agents including insulin. ADA, C-level recommendation; 
ACC/AHA, class IIa recommendation (level of evidence C).
For primary and secondary CVD risk reduction in patients 
with diabetes, providers should continue to follow the 
evidence-based recommendations for BP treatment, including 
lipid-lowering with statins, aspirin prophylaxis, smoking ces-
sation and healthy lifestyle behaviors delineated in the ADA 
Standards of Medical Care in Diabetes29 and the AHA/ADA 
guidelines for primary CVD prevention.30
The patient’s viewpoint
As newer oral diabetes agents continue to emerge on the 
market, comparative evidence is urgently required to guide 
appropriate therapy.31 A meta-analysis of the recent literature 
stated that compared with newer, more expensive agents 
(incretin, mimetics, thiazolidinediones, alpha-glucosidase 
inhibitors, meglitinides), the longer-established agents 
such as second-generation sulfonylureas and metformin 
have similar or superior effects on glycemic control, 
lipids, and other intermediate endpoints.31 Developments 
and refinements within these classes have included the 
introduction of modified-release preparations, and the emer-
gence of fixed-dose preparations with metformin and with 
novel drugs.32 The former include the thiazolidinediones, 
agents with a putative genomic mechanism of action that 
have been under continuous observation due to severe 
hepatotoxicity with the compound troglitazone as well as 
the issue of edema and the risk of precipitating heart fail-
ure in vulnerable patients.32 Rapid-acting nonsulfonylurea 
secretagogues appear to be effective and perhaps safer 
than sulfonylureas in some groups of patients with certain 
comorbidities (eg, those with renal impairment).32 Alpha-
glucosidase inhibitors have an excellent safety record and 
acarbose has been shown to retard the progression from 
impaired glucose tolerance to T2DM.32 However, their 
general use is limited by tolerability issues.
It is noteworthy that the conventional wisdom falsely 
assumes that the clinician’s key focus ought to be on reducing 
risk factors below specific levels.33 This approach, however, 
still neglects the importance of which specific strategies are 
used to modify these factors as recently discussed eagerly 
in an editorial article from Krumholz et al.33 It is stated that 
the risk/benefit ratio of interventions designed to modify 
risk factors can vary depending on the type and number 
of medications and other approaches that are concurrently 
incorporated.33 The authors assume that some medications 
may even have beneficial or harmful effects beyond their 
effect on a risk factor.33 Nowadays, also the US Food and Drug 
Administration and the European Medicines Agency focus 
more and more on patient outcomes rather than intermediate 
or surrogate markers as some therapeutic strategies.33 In the 
future, therefore, doctors will have to appreciate that improve-
ment of risk factor levels or other intermediate outcomes 
may not necessarily predict its effect on individual patient 
outcomes.33 In the general interest of promoting good care 
in patients with T2DM, national guidelines and performance 
measures have been constructed that encourage treatment 
geared toward achieving ambitious goals for levels of HbA1c, 
lipids, and BP.33 It is important, however, to realize that these 
treatment goals generally do not specify the strategy behind to 
acheive a treatment target.33 Future clinical studies therefore Vascular Health and Risk Management 2009:5 868
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will have to consider treatment strategies and performance 
measures appreciating the assessment of net clinical benefit 
based on events averted or lives improved.33 The promulga-
tion of those strategies that are shown to be effective will 
serve as an incentive for drug and device developers to 
provide evidence about patient outcomes, not just about 
how a drug or device affects intermediate outcomes.33 Mov-
ing practice toward evidence-based strategies must ensure 
that in implementing quality measures we are always acting 
in the patient’s best interests (‘individualized medicine’).33 
The recently published randomized control trials in T2DM, 
namely ACCORD, ADVANCE, VADT and UKPDS post-
trial, demonstrate the complexity of interpretation of clinical 
trails and that we need to understand a strategy’s effects on 
people, not just on surrogate endpoints.
Conclusions
The most compelling message from all recent cardiovascular 
studies in patients with T2DM is that near-normal glycemic 
control for a median of 3.5 to 5 years does not reduce 
cardiovascular events within that time frame. However, the 
ADVANCE trial reconfirmed the predicted reductions in 
new-onset microalbuminuria and nephropathy observed in 
the UKPDS.34 A troubling finding from the ACCORD trial 
is that near-normal glucose control (achieved with the use of 
combination therapy incorporating heavy use of thiazolidin-
ediones, sulfonylureas, metformin and insulin) is associated 
with significantly increased risks of death from any cause 
and death from cardiovascular causes, the very outcomes the 
trial was designed to prevent.
The results of the ACCORD and ADVANCE studies 
should be interpreted in the context of comprehensive care 
of patients with T2DM. There is clear evidence that aspirin, 
statins and the targeted lowering of BP are each associated 
with substantial reductions in cardiovascular risk in patients 
with T2DM; there may be even greater benefit when these 
reductions are achieved together.3,4 The associated therapies 
are evidence-based, widely endorsed, and worthwhile but 
can be difficult, time-consuming and resource intensive 
to implement, even when care is provided in a dedicated 
diabetes center. Before new targets are defined, it is worth 
reflecting that the currently established targets for hypergly-
cemia, hypertension and hyperlipidemia are achieved only 
in few patients (10%).29,30 Clinicians caring for patients 
with T2DM should continue to focus on smoking cessation, 
dietary and exercise counseling, BP control, and providing 
aspirin and statins to a greater extent than achieved even 
in the ADVANCE and ACCORD studies. For now, rather 
than changing our current glycemic target, we may best 
serve our patients with T2DM by implementing programs 
to help more of them reach the currently recommended 
goals.29 Medical societies such as the ADA or the German 
Diabetes Association continue to advise most people with 
T2DM to strive for an HbA1c of 7% but it also stresses the 
need for individualization of treatment goals depending on 
patient factors including comorbidities (Figure 1).29 In view 
of the recent controversy, the ADA has advised that T2DM 
patients who have existing CVD or multiple cardiovascular 
risk factors should consult with their healthcare team about 
their ‘individualized’ treatment goals.29 On the basis of the 
data presented, special consideration may now need to be 
given to high-risk patients with multiple risk factors and 
heart disease. A target HbA1c level of approximately 7% 
may be appropriate in this high-risk population, especially 
when the use of aggressive pharmacologic therapy is under 
consideration. As clearly stated by the investigators in the 
ACCORD trial, the potential existed for undetected adverse 
effects owing to an increased number of changes in drug 
regimens and an increased use of multiple drug classes and 
at increased doses. Thus, all recent studies are important 
contributions to the field but do not provide a definitive 
answer to the problem of glycemic control and CVD. 
If hypoglycemia was indeed a contributing cause of death 
in the ACCORD trial, future studies of cardiovascular risk 
reduction should focus on targeting near-normal glycemic 
levels with the use of strategies and therapies associated with 
a lower risk of hypoglycemia. Other ongoing clinical trials 
may provide additional clarification in the near future with 
this regard.11,35–37
Summary
The contribution of glucose lowering to the reduction of 
macrovascular events in UKPDS and the ADVANCE and 
ACCORD trials appears to be minimal, at least in the first 
few years of treatment. In patients with recently recognized 
diabetes with no prior CVD events, glycemic control to normal 
or near-normal levels appears to be effective in preventing 
CVD events and mortality. In patients with established T2DM 
(8 to 10 or more years) and recognized CVD, however, 
glycemic control to normal or near-normal levels does not 
reduce the risk of further CVD events or mortality. Although 
improved glucose control can clearly protect against the 
development of microvascular complications, the absence 
of a reduction in macrovascular events implicates an 
additive effect of nonglycemic risk factors that often 
accompany diabetes, such as hypertension, hyperlipidemia Vascular Health and Risk Management 2009:5 869
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Diagnosis T2DM
Combination therapies of 
oral and/or subcutaneous
antidiabetic drugs
• metformin/acarbose
• metformin/DPP-4 inhibitor
• metformin/GLP-1 analogue
• metformin/glitazone
• metformin/sufonylurea
• metformin/glinide
(alphabetical listing)
Combination therapies of
oral antidiabetic drugs
(OAD) and insulin   
OAD (mainly metformin) +
basal insulin
other options:
OAD (mainly metformin) +
prandial insulin therapy
Intensification of insulin therapy
• intensified insulin therapy (ICT)
• conventional therapy (CT), if ICT fails/not indicated
• combination with metformin, if CI/IN non-existent 
• other option: combination mit pioglitazon, if CI/IN non-existent
• other option: continuous subcutaneous insulin infusion (CSII), 
if therapy goal with ICT fails
Training course, dietetic treatment, exercise treatment, metformin     
α-glucosidase inhibitors, glitazone, repaglinid, sulfonylurea (alphabetic listing)
HbA1c< 7.5% HbA1c ≥ 7.5%
HbA1c
≥ 6.5%a
after 3–6
months
HbA1c
≥ 6.5%a
after 3–6
months
HbA1c
≥ 6.5%a
after 3–6
months
In case of contraindication (CI)/intolerance (IN) of metformin and HbA1c > 6.5%* after 3–6 months under nonpharmacological: 
Figure 1 evidence-based guideline for antihyperglycemic treatment in patients with T2DM (adopted from the German Diabetes Association [Deutsche Diabetes Gesellschaft/
DDG] based on the data from the ACCORD,   ADVANCe,   VADT and UKPDS post-trial).
aReduce HbA1c level to  6.5% from 7% might be advantageous but only when:
- (severe) hypoglycemia is prevented
- weight gain does not occur
- use of multiple glucose-lowering drugs (2) or additional insulin therapy can be avoided
HbA1c should be measured every 3 months.   Therapy should be intensified if/when the target level is missed. In contrast, pharmacological dechallenge and ‘step back’ can be 
performed if the individual HbA1c remains stable over a longer time.Vascular Health and Risk Management 2009:5 870
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and hypercoagulability. Therefore, multifactorial interventions 
by aggressive management of hypertension, dyslipidemia and 
hyperglycemia, use of aspirin, and cessation of smoking 
similar to Steno-2 should be the goal of therapy. There is 
clear evidence for such an approach where benefits in terms 
of CVD outcomes remained significant up to a period of 
13 years.4
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